Animal and cell studies
The published evidence is from animals and cells. Little or nothing is published from controlled trials in people.
This page is a stub
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
How strong is the evidence
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
- Licensed medicine
A regulator has reviewed the trials and licensed it for a named use.
- Phase 3
Large randomized trials, often thousands of people, against placebo or a standard treatment.
- Phase 2
Mid-sized trials that measure dose against effect in people with the condition.
- Phase 1 and early human studies
First studies in people: safety, and how the body handles it.
- Cells and animals: PNC-27
Laboratory and animal work. An animal result is not a result in people.
- 23
- papers on PubMed
- 17
- of them in people
- 0
- randomized trials
- 2
- reviews
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
Handling and reconstitution
From powder to a measured sample
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. Read the vial
The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.
2. Add the diluent
A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.
3. Work out the strength
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. Measure the sample
Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.
The calculator below does the arithmetic and shows its working.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on PNC-27 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of PNC-27; no amount here is a recommendation.
PNC-27: on PubMed
What PubMed held for PNC-27 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 23
- papers
- 17
- in humans
- 0
- clinical trials
- 0
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study
StudyRahmani R, Darroudi M, Gharanfoli M, et al. Iranian journal of basic medical sciences, 2022. PMID 36311203
- HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells
StudyKrzesaj PK, Seydafkan S, Miller AI, et al. Annals of clinical and laboratory science, 2025. PMID 40750238
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis
StudySarafraz-Yazdi E, Mumin S, Cheung D, et al. Biomedicines, 2022. PMID 35625682
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
StudyKrzesaj P, Adler V, Feinman RD, et al. Annals of clinical and laboratory science, 2024. PMID 38802154
- Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells
ReviewPincus MR, Silberstein M, Zohar N, et al. Biomedicines, 2024. PMID 38927351
- Anti-cancer peptides from ras-p21 and p53 proteins
ReviewPincus MR, Fenelus M, Sarafraz-Yazdi E, et al. Current pharmaceutical design, 2011. PMID 21728981
Search used: ("PNC-27"[tiab]). Run it on PubMed
Research links
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for PNC-27 on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.